QPPV.COM KNOWLEDGE ASSESSMENT

Necitumumab: Classification, Mechanism, EU History and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Necitumumab: Classification, EGFR Mechanism, EU History and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An aggregate review observes several spontaneous reports of thromboembolic events. Which conclusion is justified by report counts alone?

The reports can prompt review, but raw counts do not establish incidence or comparative safety. The count establishes the event rate among treated patients. The count proves necitumumab has greater thromboembolic risk than chemotherapy. The count establishes that all reported events were caused by necitumumab.

Question 2 of 10 A serious event occurs in a report describing necitumumab exposure in 2019. Which reference should be used to assess expectedness?

The relevant historical reference safety information applicable to the exposure period. Only the current status of the EU marketing authorisation. A current label from an unrelated medicine with a similar target. The reporter's assessment of whether the event was expected.

Question 3 of 10 Which record would best demonstrate an inspection-ready assessment of a serious historical necitumumab case?

Product and regimen details, the historical label used for expectedness, follow-up, medical assessment and the reporting decision. A brief note that the product is no longer authorised, with no event assessment. A causality conclusion based only on temporal association and EGFR biology. A copy of the spontaneous report without documenting follow-up or assessment.

Question 4 of 10 How should seriousness, expectedness and causality be handled in case assessment?

They are separate determinations and should each be assessed on their own criteria. A serious event is automatically unexpected and causally related to treatment. An expected event cannot be serious or treatment-related. A plausible mechanism establishes expectedness, seriousness and causality together.

Question 5 of 10 Which set of details best supports traceability of a historical necitumumab exposure?

Product identity, batch or lot when available, dose, route, infusion date and time, and source documents. Tumour stage and the reporter's preferred causality category only. A general statement that an antibody was given, without dates or product identification. The event outcome alone, because exposure details are unnecessary for historic cases.

Question 6 of 10 A historical EU case concerns an adult with locally advanced squamous NSCLC who received necitumumab with gemcitabine and cisplatin. How should the regimen be understood?

It matches the historical EU indication and combination described for necitumumab. It was the historical EU indication only for non-squamous NSCLC treated with necitumumab alone. It was a regimen intended for small-cell lung cancer with cisplatin omitted. It was the current EU treatment recommendation because the authorisation remains active.

Question 7 of 10 For a reported cardiac arrest during historical necitumumab combination therapy, which follow-up set is most useful?

Infusion and chemotherapy timing, cardiac risk factors, concurrent medicines, electrolyte results, investigations and resuscitation details. The patient's tumour histology alone, because it determines whether the arrest was treatment-related. A single symptom term and the date of the first necitumumab dose. The reporter's suspected product only, without clinical diagnosis or event chronology.

Question 8 of 10 A reviewer argues that an event must be caused by necitumumab because EGFR inhibition provides a plausible biological explanation. What is the best response?

Mechanistic plausibility can inform assessment, but individual causality requires evaluation of the case evidence and alternatives. A plausible pathway proves causality whenever the event occurs after exposure. Mechanism is the only evidence needed when the product is a monoclonal antibody. Mechanistic plausibility means the event should not be reported as suspected.

Question 9 of 10 A patient develops a rash during treatment. Which information most directly improves clinical characterisation of the skin event?

Morphology, severity, distribution, onset, mucosal involvement, treatment and recovery. The patient's age and tumour stage alone. The name of the suspected product without a description of the skin findings. A single laboratory result collected after the rash resolved.

Question 10 of 10 Which statement best explains why chemotherapy exposure should be documented when reviewing a necitumumab case?

Gemcitabine and cisplatin can contribute to events such as marrow suppression, infection, renal injury and electrolyte changes. Chemotherapy exposure is irrelevant once an event is reported for a monoclonal antibody. Recording chemotherapy is needed only when the reporter suspects a chemotherapy product. Chemotherapy dates establish whether necitumumab's mechanism caused the event.

QPPV.com

Necitumumab: Classification, Mechanism, EU History and Pharmacovigilance Assessment

Cookie Settings